




Shape the future of cervical cancer screening: **Identify HPV 31**

The BD Onclarity™ HPV Assay with extended genotyping is the only FDA-approved HPV test that individually identifies HPV 31, which poses a higher risk for cervical precancer as compared to HPV 18 and should be managed similarly.¹⁻⁴



Extended genotyping brings value to clinical decision-making and patient care

Get specific, actionable insights on an extended set of HPV genotypes



Report multiple high-risk HPV genotypes in a single, **pooled result**⁵

May **mask the true risk** of CIN3+ disease due to HPV 31 and will likely lead to a one-year follow-up recommendation instead of an immediate colposcopy referral^{2,4}

Prohibits monitoring of genotype-specific HPV persistence beyond HPV 16 and 18²



Reports **6 high-risk HPV genotypes individually** and the other 8 high-risk genotypes in strategic, small groups^{5,6}




Can individually **identify HPV 31**, which poses a higher risk for cervical precancer as compared to HPV 18^{1,3}



Can track genotype-specific high-risk HPV persistence, the most important determinant of cervical cancer risk in women who test HPV-positive, **regardless of HPV genotype**^{2,7-9}

The **BD Onclarity™ HPV Assay with extended genotyping** allows for a **more precise, accurate** way to measure a woman's risk for developing cervical precancer compared to an assay with partial genotyping.^{2,3,7-10}

Adapt to the evolving landscape of cervical cancer screening



As the vaccinated population increases, HPV 16 and 18 are decreasing in prevalence, making it **crucial to identify the other high-risk HPV genotypes**.^{11,12}




The evolving cervical cancer screening and management guidelines and changes in HPV genotype prevalence are impacting clinical management and calling for a shift towards **HPV testing with extended genotyping**.^{2,4,11,12}

HPV 31 identification matters. Extended genotyping is critical.

Following the American Society for Colposcopy and Cervical Pathology (ASCCP) principle of **“similar management for similar risk”**, women with an immediate risk for CIN3+ disease above 4% should be referred to colposcopy.⁴

In the BD Onclarity™ HPV Assay FDA trial, women 25 years and older with HPV 31 and normal cytology had an immediate risk for CIN3+ similar to HPV 16 that exceeds the colposcopy referral threshold of 4% recommended by ASCCP management guidelines.^{3,4}

Risk of CIN3+ by HPV type in women ≥ 25 years with normal cytology



Created from information provided in Stoler MH et al. *Gynecol Oncol.* 2019;153(1):26-33.

Only an HPV assay with extended genotyping can individually identify high-risk HPV genotypes beyond HPV 16 and 18, including HPV 31²

Shape the future of cervical cancer screening with the BD Onclarity™ HPV Assay

- ✓ Provides an individual result for HPV 31, which poses a higher risk for cervical precancer as compared to HPV 18^{1,3}
- ✓ Individually identifies 6 high-risk HPV genotypes to allow for genotype-specific HPV persistence tracking, the most important determinant of cervical cancer risk in women who test HPV-positive^{2,5-9}
- ✓ The only FDA-approved HPV assay that offers extended genotyping^{5,6}
- ✓ FDA approved for the three most-common cervical cancer screening paradigms offering the flexibility you need to adopt to changing screening guidelines^{5,6}
- ✓ Consensus guidelines favor a personalized risk-based management of cervical cancer screening results with HPV testing as the foundation for risk-estimation⁴

Improve your cervical cancer screening: Identify HPV 31

Let's shape the future of women's health. Together and now.

For more information about BD Onclarity™ HPV Assay,
please visit [womens-health-solutions.bd.com](https://www.womens-health-solutions.bd.com)

References: 1. Monsonego J et al. *Gynecol Oncol.* 2015;137(1):47–54. 2. Bonde JH et al. *J Low Genit Tract Dis.* 2020;24(1):1-13. 3. Stoler MH et al. *Gynecol Oncol.* 2019;153(1):26–33. 4. Perkins RB et al. *J Low Genit Tract Dis.* 2020;24:102–31. 5. Salazar K et al. *J Am Soc Cytopath.* 2019;8:284–92. 6. BD Onclarity HPV Assay US Package Insert [8089894]. 7. Elfgrén K et al. *AM J Obstet Gynecol.* 2017;216(3):264e1–e7. 8. Radley D et al. *Hum Vaccin Immunother.* 2016;12(3):768–72. 9. Bodily J, Laimins LA. *Trends Microbiol.* 2011;19(1):33–9. 10. Bonde J et al. *Int J Cancer.* 2019;145:1033–41. 11. Wright TC et al. *Gynecol Oncol.* 2019;153(2):259–65. 12. Drolet M et al. *Lancet.* 2019;394(10197): 497–509.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA Tel: 1.800.638.8663
[bd.com](https://www.bd.com)

BD, the BD Logo and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates.
© 2022 BD. All rights reserved. (BD-54076 1387-US-0222 February 2022)

